Prosight Management, LP
CIK 1617201
13F filing for Q2 2026・No. 3,578
- Holdings
- US$580.35M
- Quarter change
- −US$29.47M
- Entries
- 36
- Net bought (estimate)
- −US$29.56M
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 5
- Sold out 15
- Cut 15
- Added 16
- Corporate actions 0
- Unchanged 0
Largest holdings
36 stocks worth US$580.35M, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| LAKEFRONT BIOTHERAPEUTICS NVSPON ADR | Added | 2,043,344 | US$61.26M | 10.56% |
| JANUX THERAPEUTICS INCCOM | Added | 3,804,481 | US$58.44M | 10.07% |
| NEKTAR THERAPEUTICSCOM NEW | Added | 810,000 | US$56.55M | 9.74% |
| BSXBOSTON SCIENTIFIC CORPCOM | Added | 1,270,273 | US$54.22M | 9.34% |
| SHATTUCK LABS INCCOM | Added | 5,957,877 | US$41.35M | 7.12% |
| INSMINSMED INCCOM PAR $.01 | New | 375,609 | US$40.05M | 6.90% |
| ALNYALNYLAM PHARMACEUTICALS INCCOM | Added | 98,080 | US$29.53M | 5.09% |
| SYNDAX PHARMACEUTICALS INCCOM | Added | 1,200,000 | US$26.23M | 4.52% |
| KURA ONCOLOGY INCCOM | Cut | 2,021,964 | US$22.18M | 3.82% |
| ALKSALKERMES PLCSHS | Cut | 394,389 | US$20.66M | 3.56% |
Sign in (free) to see its 36 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HRFiled August 14, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.